Notably, it was shown in patients with advanced non-small cell lung cancer that the survival time of amphiregulin-negative patients treated with gefitinib was significantly longer than that of amphiregulin-positive patients. The gene discussed is AREG; the disease is non-small cell lung carcinoma.